Your browser is no longer supported. Please, upgrade your browser.
Settings
OMER Omeros Corporation daily Stock Chart
OMER [NASD]
Omeros Corporation
Index- P/E- EPS (ttm)-2.08 Insider Own0.40% Shs Outstand46.68M Perf Week-0.97%
Market Cap906.99M Forward P/E- EPS next Y-0.80 Insider Trans0.00% Shs Float46.36M Perf Month26.50%
Income-101.80M PEG- EPS next Q-0.44 Inst Own54.10% Short Float27.00% Perf Quarter8.79%
Sales75.20M P/S12.06 EPS this Y-122.20% Inst Trans3.36% Short Ratio28.46 Perf Half Y39.58%
Book/sh-2.65 P/B- EPS next Y50.90% ROA-112.30% Target Price37.20 Perf Year-13.95%
Cash/sh0.68 P/C28.43 EPS next 5Y- ROE92.50% 52W Range10.30 - 27.00 Perf YTD74.42%
Dividend- P/FCF- EPS past 5Y-13.40% ROI-218.90% 52W High-28.04% Beta2.72
Dividend %- Quick Ratio1.60 Sales past 5Y79.60% Gross Margin99.50% 52W Low88.64% ATR0.87
Employees236 Current Ratio1.60 Sales Q/Q1516.50% Oper. Margin- RSI (14)65.05 Volatility4.30% 5.27%
OptionableYes Debt/Eq- EPS Q/Q57.70% Profit Margin- Rel Volume1.00 Prev Close20.12
ShortableYes LT Debt/Eq- EarningsAug 08 AMC Payout- Avg Volume439.91K Price19.43
Recom2.20 SMA2010.79% SMA5018.80% SMA20023.76% Volume441,174 Change-3.43%
May-06-19Initiated Cantor Fitzgerald Overweight $26
Jul-12-18Initiated Seaport Global Securities Buy $30
Mar-23-18Downgrade Wedbush Outperform → Neutral $47 → $19
Mar-05-18Downgrade Needham Buy → Hold
Nov-08-17Initiated H.C. Wainwright Buy $30
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-03-16Initiated Cantor Fitzgerald Buy $21
Mar-02-16Reiterated Needham Buy $30 → $28
Feb-29-16Reiterated Wedbush Outperform $65 → $62
Nov-11-15Reiterated Needham Buy $32 → $30
Aug-18-15Reiterated WBB Securities Strong Buy $60 → $75
Aug-10-15Initiated ROTH Capital Buy $38
Mar-18-15Reiterated Needham Buy $22 → $32
Feb-20-15Reiterated Maxim Group Buy $28 → $30
Feb-18-15Reiterated MLV & Co Buy $19 → $38
Aug-22-19 10:58AM  How Medical Billing Coverage Spells Success Or Failure For Drugmakers Motley Fool
Aug-14-19 09:02PM  Edited Transcript of OMER earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-19 08:30AM  Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference Business Wire +11.89%
04:23AM  Omeros (OMER) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 06:20PM  Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM  Omeros Corporation Reports Second Quarter 2019 Financial Results Business Wire
Aug-05-19 04:02PM  Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019 Business Wire
Aug-01-19 10:32AM  Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-31-19 08:30AM  Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab Business Wire
Jul-26-19 10:33AM  The Omeros (NASDAQ:OMER) Share Price Has Gained 31% And Shareholders Are Hoping For More Simply Wall St.
Jul-24-19 08:45AM  Omeros OMIDRIA® Receives Product-Specific J-Code from CMS Business Wire
Jul-11-19 02:46PM  Calls Pop as Drug Stock Gets FDA Boost Schaeffer's Investment Research
10:23AM  Omeros, FDA Agree On Endpoint For Pivotal Trial Of Small Blood Vessel Damage Treatment Benzinga
08:00AM  Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA Business Wire
Jun-14-19 11:38AM  Edited Transcript of OMER earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-05-19 08:30AM  Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA Business Wire
May-29-19 12:34PM  Is Omeros Corporation's (NASDAQ:OMER) CEO Paid At A Competitive Rate? Simply Wall St.
May-15-19 07:00AM  Omeros to Present at the UBS Global Healthcare Conference Business Wire
May-11-19 03:23PM  Omeros (OMER) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 06:25PM  Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates Zacks
05:13PM  Omeros: 1Q Earnings Snapshot Associated Press
04:02PM  Omeros Corporation Reports First Quarter 2019 Financial Results Business Wire
11:05AM  Did Hedge Funds Drop The Ball On Omeros Corporation (OMER) ? Insider Monkey
May-07-19 09:04AM  Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting Business Wire -8.78%
May-06-19 06:01PM  Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 Business Wire
May-02-19 10:33AM  Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know Zacks
May-01-19 08:30AM  Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting Business Wire
Apr-03-19 08:30AM  Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment Business Wire
Mar-19-19 08:30AM  Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation Business Wire +5.15%
Mar-13-19 10:00AM  What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? Zacks
Mar-02-19 11:57PM  Edited Transcript of OMER earnings conference call or presentation 1-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-01-19 07:30AM  Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results Business Wire +5.20%
Feb-26-19 07:00AM  Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019 Business Wire
Feb-22-19 07:45AM  Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences Discovering Underlying Factors of Influence GlobeNewswire
Feb-20-19 08:30AM  Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721 Business Wire +5.61%
Feb-14-19 03:40PM  Why Omeros Stock Jumped Today Motley Fool +9.63%
08:30AM  Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA Business Wire
Feb-12-19 08:30AM  Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors Business Wire
Jan-30-19 11:14AM  Can We See Significant Insider Ownership On The Omeros Corporation (NASDAQ:OMER) Share Register? Simply Wall St.
Jan-17-19 11:11AM  Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data Benzinga
08:15AM  Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy Business Wire
Jan-14-19 07:30AM  Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018 Business Wire
Jan-03-19 07:35AM  Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Dec-20-18 08:30AM  Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy Business Wire
Dec-11-18 07:30AM  Omeros Announces Research Collaboration with University of Cambridge Business Wire
Dec-06-18 08:30AM  Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA) Business Wire
Dec-03-18 08:30AM  Omeros Announces Additions to Senior Management Team Business Wire
08:14AM  Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-30-18 08:25AM  New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-29-18 11:12AM  Does Omeros Corporations (NASDAQ:OMER) CEO Salary Reflect Performance? Simply Wall St.
Nov-09-18 12:12PM  Here's Why Omeros Corporation Fell as Much as 24.5% Today Motley Fool -18.73%
07:32AM  The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall Benzinga
07:00AM  Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023 Business Wire
06:55AM  Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals ACCESSWIRE
Nov-08-18 05:45PM  Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:41PM  Omeros: 3Q Earnings Snapshot Associated Press
04:26PM  Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023 PR Newswire
04:02PM  Omeros Corporation Reports Third Quarter 2018 Financial Results Business Wire
Nov-05-18 07:00AM  Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018 Business Wire
Nov-03-18 12:24PM  Why Omeros Corporation Fell 37.4% in October Motley Fool
Oct-23-18 08:30AM  FDA Grants Orphan Drug Designation to Omeros OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Business Wire
07:30AM  New Research: Key Drivers of Growth for Hecla Mining, Atlas Air Worldwide, Encana, Omeros, Lowe's Companies, and Oaktree Specialty Lending Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-08-18 11:15AM  Are These Beaten-Down Clinical-Stage Biotech Stocks Buys? Motley Fool +5.51%
Oct-02-18 03:32PM  Why Omeros Corporation Stock Is Bouncing Back Today Motley Fool +10.24%
08:00AM  Today's Research Reports on Trending Tickers: Omeros and Sarepta Therapeutics ACCESSWIRE
Oct-01-18 03:15PM  Omeros stock drops 45% after kidney disease trial results MarketWatch -42.81%
02:15PM  Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy Business Wire
08:45AM  Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA® Business Wire
Sep-28-18 07:37AM  Best ETFs for 2018: Dont Sweat This Quarter for the SBIO ETF InvestorPlace
Sep-27-18 07:00AM  Omeros to Present at the 2018 Cantor Global Healthcare Conference Business Wire
Sep-12-18 10:18AM  Jim Cramer Shares Thoughts On Skyworks Solutions, Cypress Semiconductor, More Benzinga
Sep-11-18 06:57PM  Cramer's lightning round: Don't block the 'freight train' that is Skyworks Solutions' stock CNBC
Sep-07-18 07:00AM  Omeros to Present at the Morgan Stanley Global Healthcare Conference Business Wire
Sep-05-18 09:23AM  3 Biotech Stocks That Still Have Major Catalysts in September Motley Fool
Sep-04-18 04:11PM  Edited Transcript of OMER earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-28-18 07:55AM  Detailed Research: Economic Perspectives on Allegheny Technologies, Ring Energy, Aerohive Networks, Omeros, Adtalem Global Education, and BioPharmX What Drives Growth in Today's Competitive Landscape GlobeNewswire
07:30AM  European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation Business Wire
Aug-10-18 08:00AM  Today's Research Reports on Trending Tickers: Omeros and Intrexon ACCESSWIRE -18.29%
07:00AM  Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference Business Wire
Aug-09-18 05:45PM  Omeros (OMER) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:37PM  Omeros: 2Q Earnings Snapshot Associated Press
04:02PM  Omeros Corporation Reports Second Quarter 2018 Financial Results Business Wire
Aug-03-18 07:00AM  Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018 Business Wire
Aug-02-18 07:00AM  Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer Business Wire
Jul-26-18 07:30AM  Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros Drug Expire Business Wire
Jul-25-18 08:30AM  Omeros OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation Business Wire +5.30%
Jul-23-18 07:15AM  Omeros Corporation Initiates Sales of OMIDRIA® in Europe Business Wire +7.79%
Jul-17-18 07:00AM  Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction Business Wire
Jul-13-18 07:40AM  Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks ACCESSWIRE
Jun-27-18 09:15AM  Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment Business Wire
Jun-26-18 07:45AM  Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta Holding, and Seattle Genetics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-21-18 08:00AM  Report: Developing Opportunities within ABIOMED, Avid Technology, Unit, Omeros, Strayer Education, and NeoGenomics Future Expectations, Projections Moving into 2018 GlobeNewswire -5.29%
Jun-12-18 08:05AM  Breakfast Technical Briefing on Omeros and Three Other Additional Biotech Stocks ACCESSWIRE
May-29-18 07:10AM  Wired News Omeros Settles Lawsuit Against Lupin for Filing ANDA With FDA for Marketing Generic Version of OMIDRIA(R) ACCESSWIRE
May-24-18 07:00AM  Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin Business Wire
May-16-18 04:40PM  Why Omeros, Party City Holdco, and Overstock.com Slumped Today Motley Fool -18.13%
May-15-18 05:51AM  Edited Transcript of OMER earnings conference call or presentation 10-May-18 8:30pm GMT Thomson Reuters StreetEvents +7.81%
May-14-18 08:00AM  Today's Research Reports on Trending Tickers: Omeros and bluebird bio ACCESSWIRE +13.98%
May-11-18 01:29PM  Here's Why Omeros Corporation Stock Is Surging Today Motley Fool +23.31%
08:00AM  Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros Corporation ACCESSWIRE
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PDE10 (OMS824) which is in Phase II clinical trial for treating Huntington's disease and schizophrenia; PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is based in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelbon Marcia S.VP Patent and General CounselJun 07Option Exercise6.0510,00060,500210,645Jun 11 06:51 PM
Kelbon Marcia S.VP Patent and General CounselAug 31Option Exercise5.1015,52979,269200,645Aug 31 09:32 PM
Kelbon Marcia S.VP Patent and General CounselAug 31Sale25.757,529193,846192,645Aug 31 09:32 PM
Kelbon Marcia S.VP Patent and General CounselAug 30Option Exercise4.1035,000143,500227,645Aug 31 09:32 PM
Kelbon Marcia S.VP Patent and General CounselAug 30Sale24.4535,000855,750192,645Aug 31 09:32 PM